These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 20153543

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Cost effectiveness of teriparatide and PTH(1-84) in the treatment of postmenopausal osteoporosis.
    Borgström F, Ström O, Marin F, Kutahov A, Ljunggren O.
    J Med Econ; 2010; 13(3):381-92. PubMed ID: 20604678
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The clinical and economic burden of poor adherence and persistence with osteoporosis medications in Ireland.
    Hiligsmann M, McGowan B, Bennett K, Barry M, Reginster JY.
    Value Health; 2012; 15(5):604-12. PubMed ID: 22867768
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Effect of adherence on lifetime fractures in osteoporotic women treated with daily and weekly bisphosphonates.
    Danese MD, Badamgarav E, Bauer DC.
    J Bone Miner Res; 2009 Nov; 24(11):1819-26. PubMed ID: 19419313
    [Abstract] [Full Text] [Related]

  • 11. Cost of non-persistence with oral bisphosphonates in post-menopausal osteoporosis treatment in France.
    Cotté FE, De Pouvourville G.
    BMC Health Serv Res; 2011 Jun 25; 11():151. PubMed ID: 21702989
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Annual zoledronic acid for osteoporosis.
    BMJ Group.
    Drug Ther Bull; 2008 Dec 25; 46(12):93-6. PubMed ID: 19056701
    [Abstract] [Full Text] [Related]

  • 15. Cost-effectiveness of strontium ranelate versus risedronate in the treatment of postmenopausal osteoporotic women aged over 75 years.
    Hiligsmann M, Bruyère O, Reginster JY.
    Bone; 2010 Feb 25; 46(2):440-6. PubMed ID: 19716940
    [Abstract] [Full Text] [Related]

  • 16. Cost effectiveness of secondary vs tertiary prevention for post-menopausal osteoporosis.
    Mueller D, Gandjour A.
    Appl Health Econ Health Policy; 2011 Jul 01; 9(4):259-73. PubMed ID: 21682353
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Cost-effectiveness of strontium ranelate for the prevention and treatment of osteoporosis.
    Hiligsmann M, Vanoverberghe M, Neuprez A, Bruyère O, Reginster JY.
    Expert Rev Pharmacoecon Outcomes Res; 2010 Aug 01; 10(4):359-66. PubMed ID: 20715911
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.